Two studies showed that Omicron’s hospitalisation risk is less than the Delta variant. A study from Scotland found that the risk of hospitalisation from Omicron is two-thirds lesser than the earlier variants, although the risk of infection is much higher.
“Markets are taking comfort from their global counterparts, but it will be difficult to extend the rebound amid updates on rising Covid cases. Participants should continue with a cautious approach and focus on stock selection. Apart from information technology, we see select counters from pharmaceutical and fast-moving consumer goods doing well. However, the underperformance of the banking pack remains a worry,” said Ajit Mishra, vice-president-research, Religare Broking.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)